Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Ook SIRNA

BioPharma« Terug naar discussie overzicht

Ook SIRNA

Volgen
1.786 Posts
Pagina: «« 1 ... 82 83 84 85 86 ... 90 »» | Laatste | Omlaag ↓
  8. [verwijderd] 1 maart 2006 22:06
    SAN FRANCISCO, March 1 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI) today reported financial results for the fourth quarter and year ended December 31, 2005.

    For the quarter ended December 31, 2005, Sirna reported a net loss of $5.8 million, or $0.10 per share, compared to a net loss of $8.9 million, or $0.23 per share, for the same period in 2004. Net loss for the year ended December 31, 2005 was $23.9 million, or $0.48 per share, compared to $28.9 million, or $0.81 per share, for the same period last year.

    Revenues for the fourth quarter of 2005 were $1.0 million, up from $692,000 for the same quarter in 2004. Revenues for the twelve months ended December 31, 2005 were $4.9 million compared to $1.5 million during the same period in 2004. Revenues increased during 2005 compared to 2004 primarily due to a $1.8 million success milestone payment received in July 2005 related to its oncology collaboration with Eli Lilly and Company, and a $1.7 million increase in contract manufacturing revenues. In addition, the Company recognized $417,000 in revenue from the $5.0 million cash up-front fee received from Allergan, Inc., in September 2005. This up-front fee is being amortized over the development period.

    Operating expenses decreased to $7.3 million and $29.9 million for the three and twelve-month periods ended December 31, 2005, respectively, compared to $9.6 million and $30.6 million for the same periods in 2004. The quarter-to-quarter decrease is primarily due to a $1.9 million R&D expense in the fourth quarter of 2004 related to the acquisition of Skinetics, Inc., which has become the foundation for the Company's dermatology program.

    Sirna ended the fourth quarter with $45.7 million in cash and marketable securities. The Company expects to use approximately $25.0 million in cash to fund 2006 operations, to be partially offset by potential new collaboration fees received during the year.

    "Sirna had an exciting fourth quarter," stated Howard W. Robin, Sirna President and CEO. "Most importantly, we selected a clinical candidate, Sirna-034, in our hepatitis C antiviral program. This candidate was selected on the basis of impressive systemic efficacy in multiple animal model systems, including non-human primates, which is a first in the field of RNAi-based therapeutics. We expect to initiate Phase 1 clinical trial enabling toxicology studies this month and to file an IND for Sirna-034 in the fourth quarter this year."

    Recent highlights include:

    * The completion of Phase 1 clinical trial of Sirna-027 for age-related
    macular degeneration demonstrated that Sirna's short interfering RNA
    (siRNA) molecule targeting Vascular Endothelial Growth Factor
    Receptor-1 (VEGFR-1) is safe and well tolerated. Twenty-five of
    26 patients (96%) showed visual acuity stabilization and 23% of those
    patients experiencing clinically significant improvement in visual
    acuity eight weeks after a single injection. The trial also showed a
    relevant decrease in central foveal thickness measured by ocular
    coherence tomography (OCT), which is the first demonstration of
    biological activity of a siRNA in humans.

    * The selection of Sirna's hepatitis C virus (HCV) drug candidate,
    Sirna-034. The compound consists of multiple, chemically optimized,
    siRNAs formulated in Sirna's proprietary nanoparticle technology.
    These siRNAs target highly conserved sequences in the Hepatitis C viral
    genome and is designed to inhibit viral replication and dramatically
    reduce the generation of drug resistant mutant variants. In
    preparation for Phase 1 clinical trials, Sirna has begun manufacturing
    material for its preclinical toxicology studies to be followed by the
    filing of an IND application with the FDA during fourth quarter of
    2006. Sirna is the first company to demonstrate systemic efficacy of
    siRNAs in non-human primates.

    * The exclusive worldwide license to the Rana Patents on
    chemically-modified short interfering RNA (siRNA) from the University
    of Massachusetts. The license is complimentary to Sirna's existing
    chemical modification-related intellectual property portfolio, which
    collectively provide Sirna a strong patent position in the discovery,
    development and commercialization of chemically optimized siRNAs. In
    addition, in January the United States Patent and Trademark Office
    granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and
    manufacturing of ribonucleic acids (RNA). The patent broadly covers a
    process for the synthesis, deprotection and purification of nucleic
    acids with one or more ribonucleotides.

    * The addition of the company to the NASDAQ Biotechnology Index
    (Nasdaq: ^NBI), effective on November 21, 2005.

    Howard W. Robin and the Sirna senior management team will discuss progress to date in Sirna's clinical and preclinical programs, business development efforts as well as the fourth quarter financial results during a conference call on Wednesday, March 1st at 4:30 p.m. EST (2:30 p.m. MST and 1:30 p.m. PST).

  19. ludwig mack 3 maart 2006 21:44
    quote:

    Dalma schreef:

    daarom. heb daarvoor insmed gekocht (van de winst)..

    ik weet totaal niet waarom ie stijgt, daar hou ik niet van. Tis zo onduidelijk als het maar zijn kan..straks doen ze nog een shelf offering of weet ik veel wat..

    pak op deze 5k zo'n 120% winst :))
    ok, mooi !
    ja, denk dat er een paar krachten achter zitten die wijzen op het revolutionaire karakter van rnai, en dat men gaat speculeren .....
    tijdens het c.c. was men wel erg voorbarig in de resultaten.
  20. gustaaf1e 3 maart 2006 23:49
    quote:

    Dalma schreef:

    daarom. heb daarvoor insmed gekocht (van de winst)..

    ik weet totaal niet waarom ie stijgt, daar hou ik niet van. Tis zo onduidelijk als het maar zijn kan..straks doen ze nog een shelf offering of weet ik veel wat..

    pak op deze 5k zo'n 120% winst :))
    Verwacht zeker geen emissie. Zie 8 posts hiervoor.
    goedkeuring zal nog wel poos op zich laten wachten,(eind volgend jaar?) maar voldoende eigen inkomsten en kansrijke ontwikkelingen in de pipeline.
    G
    had een prachtige dag.
1.786 Posts
Pagina: «« 1 ... 82 83 84 85 86 ... 90 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
SBM Offshore 20,780 +2,45 +13,37%
EBUSCO HOLDING 0,626 +0,05 +8,19%
AMG Critical Materials N.V. 16,410 +0,79 +5,06%
ForFarmers 3,780 +0,18 +5,00%
NN Group 47,270 +1,65 +3,62%
Wereldhave 15,260 +0,34 +2,28%
PostNL 1,070 +0,02 +2,20%
SIGNIFY NV 21,280 +0,44 +2,11%
Nedap N.V. 60,000 +1,20 +2,04%
TomTom 4,470 +0,09 +2,01%
WDP 21,220 +0,40 +1,92%
PROSUS 45,090 +0,79 +1,77%
OCI 11,020 +0,16 +1,43%
CTP 16,340 +0,18 +1,11%
FASTNED 19,980 +0,22 +1,11%
NX FILTRATION 3,275 +0,04 +1,08%
Brunel 9,460 +0,10 +1,07%
IMCD 146,900 +1,35 +0,93%
NSI 22,300 +0,20 +0,90%
Eurocommercial Properties 23,950 +0,20 +0,84%
Arcadis 50,400 +0,40 +0,80%
Sif Holding 11,140 +0,08 +0,72%
BESI 117,000 +0,80 +0,69%
INPOST 17,310 +0,11 +0,64%
Kendrion 10,260 +0,06 +0,59%
RANDSTAD NV 38,390 +0,19 +0,50%
AMX 857,32 +3,50 +0,41%
TKH 37,460 +0,14 +0,38%
Basic-Fit 22,260 +0,08 +0,36%
VASTNED 28,300 +0,10 +0,35%
Avantium 1,826 +0,01 +0,33%
Pharming 0,875 +0,00 +0,29%
ASCX 1.335,83 +3,49 +0,26%
ING 16,440 +0,02 +0,10%
SHELL PLC 32,590 +0,01 +0,02%

Dalers

instrument koers absoluut verschil relatief verschil
Aegon 5,862 -0,61 -9,37%
Vopak 39,700 -2,30 -5,48%
THEON INTERNAT 17,420 -0,66 -3,65%
Fagron 19,380 -0,72 -3,58%
JUST EAT TAKEAWAY 12,250 -0,40 -3,16%
Flow Traders 25,640 -0,48 -1,84%
ADYEN NV 1.804,800 -31,00 -1,69%
HEIJMANS KON 33,350 -0,55 -1,62%
ArcelorMittal 26,820 -0,40 -1,47%
ASR Nederland 48,660 -0,68 -1,38%
DSM FIRMENICH AG 100,700 -1,10 -1,08%
ASML 709,900 -7,60 -1,06%
ASMI 566,400 -6,00 -1,05%
Accsys 0,495 -0,01 -1,00%
Ahold Delhaize 33,510 -0,32 -0,95%
Galapagos 25,340 -0,24 -0,94%
AALBERTS NV 36,080 -0,34 -0,93%
Alfen N.V. 12,200 -0,11 -0,85%
Wolters Kluwer 175,500 -1,35 -0,76%
Fugro 14,490 -0,09 -0,62%
Corbion 22,540 -0,14 -0,62%
ALLFUNDS GROUP 4,858 -0,03 -0,61%
Akzo Nobel 57,500 -0,32 -0,55%
Aperam 29,440 -0,16 -0,54%
Heineken 77,560 -0,42 -0,54%
Air France-KLM 8,368 -0,04 -0,50%
AZERION 1,640 -0,01 -0,49%
RELX 48,080 -0,22 -0,46%
KPN 3,483 -0,02 -0,43%
EXOR NV 93,000 -0,40 -0,43%
Van Lanschot Kempen NV 48,300 -0,20 -0,41%
AEX 938,58 -3,70 -0,39%
Sligro 10,580 -0,04 -0,38%
Philips Koninklijke 24,000 -0,08 -0,33%
ACOMO 18,220 -0,06 -0,33%
CM.COM 6,470 -0,02 -0,31%
UNILEVER PLC 53,020 -0,16 -0,30%
ABN AMRO BANK N.V. 17,555 -0,05 -0,26%
BAM 4,870 -0,01 -0,25%
JDE PEET'S 16,920 -0,04 -0,24%
RENEWI 10,240 -0,02 -0,19%
UMG 28,150 -0,05 -0,18%
B&S Group SA 4,305 -0,01 -0,12%
vlag naam koers verschil relatief verschil
AEX 938,58 -3,70 -0,39%
AEX GR 3.688,15 -14,54 -0,39%
DE40 22.314,65 -118,98 -0,53%
FTSE 100 8.662,97 -49,56 -0,57%
Europe50^ 5.461,03 -0,14 0,00%
US30^ 44.183,70 0,00 0,00%
Nasd100^ 22.069,60 0,00 0,00%
US500^ 6.119,18 0,00 0,00%
Japan225^ 38.585,80 0,00 0,00%
VD-NEW 20,38 +0,50 +2,50%
#/^ Index indications calculated real time, zie disclaimer